News

Public · Published

CBLL: Revenue grew 30%, but higher spending widened Q3 losses as hospital adoption passed 700

Q3 revenue grew 30% year over year to $29.3M, while net loss widened to $21.4M as operating costs rose. Hospital adoption passed 700, and the company said $117.5M in cash and marketable securities supports at least 12 months of planned needs.

Published:

Updated:

What happened

Q3 revenue grew 30% year over year to $29.3M, while net loss widened to $21.4M as operating costs rose. Hospital adoption passed 700, and the company said $117.5M in cash and marketable securities supports at least 12 months of planned needs.

Confirmed

Global impact / market context

Revenue is growing, but the company still spends more than it earns, so the net loss widened. The $117.5M cash cushion means it can fund at least 12 months of planned needs without raising outside money, reducing near-term financing pressure on the stock.

Analyst inference

Investors weighing CBLL face a trade-off: fast 30% revenue growth and over 700 hospitals using the product versus a $21.4M quarterly loss. With cash covering only at least 12 months of plans, future spending and any new share sales stay central.

Analyst inference

What to watch

  1. Watch whether Q3 revenue keeps growing at a similar pace to the 30% year-over-year rate reported for the quarter, since slower growth alongside rising operating costs would widen losses further. Confirmed
  2. Company guidance would help: watch for management targets on hospital adoption beyond 700, spending plans, and how the 2026 clearances are expected to add products and revenue over coming quarters. Proposed
  3. Track the $117.5M in cash and marketable securities as spending rises. If losses persist, the 12-month runway shortens, which means the company may need to raise money through borrowing or share sales. Analyst inference

Evidence

  • Original source link unavailable